Endothelial progenitor cells in cardiovascular diseases

doi:10.4252/wjsc.v6.i3.355

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 6, Issue 3

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9698)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-6) series.

Item

Count

PDF

1436

WORD

370

HTML

5125

Figures (1-3)

206

Tables (1-6)

180

Sum=7317

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1186

Download

1195

Sum=2381

Jul 26, 2014 (publication date) through Nov 23, 2024

Times Cited of This Article

Times Cited (116)

Journal Information of This Article

Publication Name

World Journal of Stem Cells

ISSN

1948-0210

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Stem Cells. Jul 26, 2014; 6(3): 355-366
Published online Jul 26, 2014. doi: 10.4252/wjsc.v6.i3.355

Full Size Figure Download Figure

Figure 3 Cardiovascular-related pharmacological therapies which may affect numbers and function of endothelial progenitor cells. TZDs: Thiazolidinedione; DPP4I: Dipeptidyl peptidase 4 inhibitors; ARBs: Angiotensin II receptor blockers; ACEI: Angiotensin converting enzyme inhibitors; CCBs: Calcium channel blockers.

Citation: Lee PSS, Poh KK. Endothelial progenitor cells in cardiovascular diseases. World J Stem Cells 2014; 6(3): 355-366
URL: https://www.wjgnet.com/1948-0210/full/v6/i3/355.htm
DOI: https://dx.doi.org/10.4252/wjsc.v6.i3.355